Overview

A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

To investigate the efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer following administration of rebamipide and to determine the optimal dose of rebamipide.

Phase:

Phase 2

Details

Lead Sponsor:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

Rebamipide